人類乳突病毒（HPV）相關疾病市場－全球產業規模、佔有率、趨勢、機會、預測：按適應症、治療方法、最終用戶、地區和競爭格局分類，2021-2031年

全球人類乳突病毒 (HPV) 相關疾病市場預計將從 2025 年的 282.3 億美元成長到 2031 年的 405.7 億美元，複合年成長率為 6.23%。

該市場涵蓋預防性疫苗、診斷測試以及針對人類乳突病毒（HPV）感染相關疾病（如子宮頸癌和生殖器疣）的治療方法方法的研發和商業化。推動這一成長的關鍵因素包括各國強制免疫接種的廣泛普及以及向分子篩檢方案的策略性轉變，後者能夠實現疾病的早期檢測。這些因素正在催生對超越短暫行業趨勢的全面性醫療解決方案的根本性需求。

然而，在低收入地區，如何公平地獲得昂貴的疫苗和先進治療方法仍然是市場面臨的重大挑戰，這限制了其在全球的應用。儘管預防方面取得了進展，但美國癌症協會估計，到2025年，美國將新增約13,360例浸潤性子宮頸癌病例，凸顯了推動該領域發展的迫切醫療需求。這項統計數據表明，這些干預措施仍然至關重要。

市場促進因素

各國免疫規劃的廣泛擴展是市場成長的主要驅動力。這是因為各國政府正在加速將預防措施納入公共衛生政策，以控制長期醫療保健成本。這種向全民覆蓋的策略轉變，為製造商提供了批量採購契約，並促進了已開發經濟體和新興經濟體產品的穩定分銷。根據世界衛生組織（世衛組織）2024年7月發布的《免疫接種率預測》，預計到2023年，全球女孩人類乳突病毒（HPV）疫苗首輪接種率將達到27%，標誌著先前下降趨勢的顯著回升。此類政府主導的措施正在創造穩定的商業環境，並刺激對疫苗供應鏈和接種基礎設施的進一步投資。

同時，病毒感染疾病及其相關惡性腫瘤在全球範圍內的持續蔓延，迫切需要改進診斷和治療方法。疾病負擔沉重，迫使醫療衛生系統將資源投入早期檢測技術和有效治療方案中，從而維持整個市場的需求。根據世界衛生組織（世衛組織）2024年3月發布的子宮頸癌概況介紹，2022年全球報告的子宮頸癌新病例估計為66萬例，死亡病例為35萬例。這項流行病學負擔凸顯了疾病管理領域持續創新至關重要。默克公司2023年發布的全球人類乳突病毒（HPV）疫苗銷售額達89億美元，也反映了此類干預措施的經濟規模。

市場挑戰

低收入地區取得昂貴疫苗和先進治療方法的途徑存在差異，嚴重限制了全球HPV相關疾病市場的商業性擴張。高所得國家受益於完善的醫療基礎設施和報銷模式，而發展中國家往往缺乏實施高品質預防和治療性介入所需的資金。這種經濟差距造成了市場碎片化的局面，即使在疾病負擔最重的地區，大型製藥公司也無法商業性。因此，分子診斷和生物製藥的高昂單位成本阻礙了這些人口稠密地區的廣泛應用，導致市場成長停滯，並有效地限制了市場總規模的潛在成長。

這些物流和資金瓶頸限制了收入來源，使其僅限於飽和的已開發經濟體，從而阻礙了整個產業的進一步擴張。近期疫苗接種數據凸顯了這種差距的嚴重性。全球疫苗免疫聯盟（Gavi）在其2025年報告中指出，受支持的低收入國家的人類乳突病毒（HPV）疫苗接種率僅為25%，顯示與全球目標相比，這些國家在獲得預防性醫療保健方面存在顯著滯後。如此低的接種率表明，資金障礙直接阻礙了該行業利用全球需求的能力，從而減緩了整體市場的發展勢頭。

市場趨勢

家用自採集試劑盒的出現從根本上改變了子宮頸癌篩檢的去中心化模式，使個人能夠自行採集檢體，有效繞過了臨床骨盆檢查帶來的後勤和心理障礙。這一趨勢利用FDA核准的醫療設備來解決服務不足人口篩檢率停滯不前的問題，從而將具有商業性可行性的患者群體擴展到傳統醫療機構之外。為了佐證該方法的臨床有效性，Teal Health於2025年5月宣布，其獲得FDA已通過核准的家用自採集設備Teal Wand對子宮頸癌前病變的檢出率達到了96%，其性能與標準的醫生輔助檢體相當。這項監管里程碑標誌著診斷方式正朝著以消費者為中心的方向轉變，使檢測率擺脫臨床基礎設施的限制。

同時，市場正轉向研發HPV治療性疫苗，其目的不僅在於預防病毒感染，更在於治療已發生的感染疾病。與現有的預防性疫苗不同，這些新型免疫療法旨在誘導針對致癌性蛋白的靶向T細胞反應，為復發性呼吸道乳頭狀瘤病等對預防性治療無效的患者提供非手術治療方法。例如，Inovio Pharmaceuticals公司於2025年1月報告稱，在其治療性DNA候選藥物INO-3107的治療下，50%的患者達到完全緩解，且在評估期間無需手術干預。這項療效凸顯了治療性生物製藥透過取代侵入性手術標準療法而獲得顯著市場佔有率的潛力。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球人類乳突病毒（HPV）相關疾病市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 適應症（肛門上皮內瘤、肛門癌、子宮頸癌、子宮頸上皮內瘤、生殖器濕疣）
  • 治療方法（預防、治療）
  • 依最終使用者（醫院/診所、門診中心、其他）分類
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美人類乳突病毒（HPV）相關疾病市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國別分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲人類乳突病毒（HPV）相關疾病市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國別分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區人類乳突病毒（HPV）相關疾病市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國別分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東與非洲人乳突病毒（HPV）相關疾病市場展望

• 市場規模及預測
• 市佔率及預測
• 中東與非洲：國別分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美洲人類乳突病毒（HPV）相關疾病市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國別分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進因素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 近期趨勢

第13章 全球人類乳突病毒（HPV）相關疾病市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的議價能力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Alembic Pharmaceuticals
• AstraZeneca plc
• Bausch Health Companies Inc
• Biocon Ltd.
• Bristol-Myers Squibb Co.
• Eli Lilly and Company.
• F. Hoffmann-La Roche Ltd
• GlaxoSmithKline plc
• Merck & Co., Inc.
• Novartis AG
• Pfizer, Inc.

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Human Papillomavirus (HPV) Associated Disorders Market is projected to grow from USD 28.23 billion in 2025 to USD 40.57 billion by 2031, at a compound annual growth rate (CAGR) of 6.23%. This market encompasses the development and commercialization of prophylactic vaccines, diagnostic assays, and therapeutic treatments for conditions linked to HPV infection, such as cervical cancer and genital warts. Key drivers facilitating this growth include the widespread expansion of national immunization mandates and a strategic shift towards molecular screening protocols, which enhance early disease detection. These factors establish a foundational demand for comprehensive care solutions, transcending transient industry trends.

Nevertheless, the market faces a significant challenge concerning equitable access to costly vaccines and advanced therapeutics in lower-income territories, which restricts its global penetration. The critical medical necessity driving this sector, despite advancements in prevention, is validated by the American Cancer Society's estimate of approximately 13,360 new cases of invasive cervical cancer diagnosed in the United States in 2025. This statistic highlights the ongoing importance of these interventions.

Market Driver

The widespread expansion of national immunization programs serves as a primary catalyst for market growth, as governments increasingly integrate prophylactic regimens into public health mandates to curb long-term healthcare costs. This strategic shift toward universal coverage secures high-volume procurement contracts for manufacturers and fosters consistent product uptake across both developed and emerging economies. According to the World Health Organization's 'Immunization Coverage Estimates' release in July 2024, the global coverage for the first dose of the human papillomavirus vaccine among girls rose to 27% in 2023, indicating a significant recovery from previous declines. Such government-backed initiatives create a stable commercial environment that encourages further investment in vaccine supply chains and accessibility infrastructure.

Concurrently, the persistent global prevalence of viral infections and associated malignancies drives an urgent necessity for improved diagnostic and therapeutic modalities. The high burden of disease compels healthcare systems to allocate resources toward early detection technologies and effective treatment protocols, thereby sustaining demand for the broader market portfolio. The World Health Organization's 'Cervical Cancer' fact sheet from March 2024 reported an estimated 660,000 new cases of cervical cancer and 350,000 deaths globally in 2022. This epidemiological load underscores the critical need for continued innovation in disease management, with Merck & Co., Inc. reporting worldwide sales of $8.9 billion for its dedicated human papillomavirus vaccine franchise in 2023, highlighting the substantial economic scale of these interventions.

Market Challenge

Inequitable access to costly vaccines and advanced therapeutics in lower-income territories presents a significant constraint on the commercial expansion of the Global HPV Associated Disorders Market. While high-income nations benefit from established healthcare infrastructure and reimbursement models, developing regions frequently lack the financial capacity to procure premium prophylactic and therapeutic interventions. This economic disparity creates a fragmented landscape where regions with the highest disease burden remain commercially inaccessible to major pharmaceutical developers. Consequently, the market experiences stalled volume growth, as the high unit costs of molecular diagnostics and biologics prevent widespread adoption in these densely populated areas, effectively capping the total addressable market.

This logistical and financial bottleneck limits revenue streams to saturated developed economies, stifling broader industrial scalability. The magnitude of this penetration gap is evident in recent immunization data, with Gavi, the Vaccine Alliance, reporting in 2025 that human papillomavirus (HPV) vaccine coverage in supported lower-income countries had reached only 25%, highlighting a severe lag in accessing preventative care compared to global targets. Such low penetration rates demonstrate how financial barriers directly impede the sector's ability to capitalize on global demand, thereby hampering overall market momentum.

Market Trends

The emergence of at-home self-sampling kits is fundamentally decentralizing cervical screening by enabling private sample collection, effectively bypassing the logistical and psychological barriers associated with clinical pelvic exams. This trend leverages FDA-approved devices to address stagnating screening rates in underserved demographics, thereby expanding the commercially addressable patient population beyond traditional healthcare settings. Validating the clinical efficacy of this approach, Teal Health announced in May 2025 that its FDA-approved Teal Wand at-home self-collection device demonstrated a 96% detection rate for cervical precancer, matching the performance of standard clinician-collected samples. This regulatory milestone signals a strategic pivot toward consumer-centric diagnostics that dissociate testing volumes from clinical infrastructure constraints.

Simultaneously, the market is shifting toward therapeutic HPV vaccine development to treat established infections rather than solely preventing viral acquisition. Unlike prophylactic incumbents, these novel immunotherapies are designed to elicit targeted T-cell responses against oncogenic proteins, offering non-surgical interventions for patients with conditions like recurrent respiratory papillomatosis who derive no benefit from preventative regimens. Highlighting this sector's clinical progress, Inovio Pharmaceuticals reported in January 2025 that 50% of patients treated with the therapeutic DNA medicine candidate INO-3107 achieved a complete response, requiring no surgical intervention during the evaluation period. This efficacy underscores the potential for therapeutic biologics to capture significant market share by replacing invasive surgical standards of care.

Key Market Players

• Alembic Pharmaceuticals
• AstraZeneca plc
• Bausch Health Companies Inc
• Biocon Ltd.
• Bristol-Myers Squibb Co.
• Eli Lilly and Company.
• F. Hoffmann-La Roche Ltd
• GlaxoSmithKline plc
• Merck & Co., Inc.
• Novartis AG
• Pfizer, Inc.

Report Scope

In this report, the Global Human Papillomavirus (HPV) Associated Disorders Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Human Papillomavirus (HPV) Associated Disorders Market, By Indication

• AIN
• Anal Cancer
• Cervical Cancer
• CIN
• Genital Warts

Human Papillomavirus (HPV) Associated Disorders Market, By Therapy

• Prevention
• Treatment

Human Papillomavirus (HPV) Associated Disorders Market, By End user

• Hospitals & Clinics
• Ambulatory Care Centers
• Others

Human Papillomavirus (HPV) Associated Disorders Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Human Papillomavirus (HPV) Associated Disorders Market.

Available Customizations:

Global Human Papillomavirus (HPV) Associated Disorders Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Human Papillomavirus (HPV) Associated Disorders Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Indication (AIN, Anal Cancer, Cervical Cancer, CIN, Genital Warts)
  • 5.2.2. By Therapy (Prevention, Treatment)
  • 5.2.3. By End user (Hospitals & Clinics, Ambulatory Care Centers, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Human Papillomavirus (HPV) Associated Disorders Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Indication
  • 6.2.2. By Therapy
  • 6.2.3. By End user
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Human Papillomavirus (HPV) Associated Disorders Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Indication
      • 6.3.1.2.2. By Therapy
      • 6.3.1.2.3. By End user
  • 6.3.2. Canada Human Papillomavirus (HPV) Associated Disorders Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Indication
      • 6.3.2.2.2. By Therapy
      • 6.3.2.2.3. By End user
  • 6.3.3. Mexico Human Papillomavirus (HPV) Associated Disorders Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Indication
      • 6.3.3.2.2. By Therapy
      • 6.3.3.2.3. By End user

7. Europe Human Papillomavirus (HPV) Associated Disorders Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Indication
  • 7.2.2. By Therapy
  • 7.2.3. By End user
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Human Papillomavirus (HPV) Associated Disorders Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Indication
      • 7.3.1.2.2. By Therapy
      • 7.3.1.2.3. By End user
  • 7.3.2. France Human Papillomavirus (HPV) Associated Disorders Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Indication
      • 7.3.2.2.2. By Therapy
      • 7.3.2.2.3. By End user
  • 7.3.3. United Kingdom Human Papillomavirus (HPV) Associated Disorders Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Indication
      • 7.3.3.2.2. By Therapy
      • 7.3.3.2.3. By End user
  • 7.3.4. Italy Human Papillomavirus (HPV) Associated Disorders Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Indication
      • 7.3.4.2.2. By Therapy
      • 7.3.4.2.3. By End user
  • 7.3.5. Spain Human Papillomavirus (HPV) Associated Disorders Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Indication
      • 7.3.5.2.2. By Therapy
      • 7.3.5.2.3. By End user

8. Asia Pacific Human Papillomavirus (HPV) Associated Disorders Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Indication
  • 8.2.2. By Therapy
  • 8.2.3. By End user
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Human Papillomavirus (HPV) Associated Disorders Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Indication
      • 8.3.1.2.2. By Therapy
      • 8.3.1.2.3. By End user
  • 8.3.2. India Human Papillomavirus (HPV) Associated Disorders Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Indication
      • 8.3.2.2.2. By Therapy
      • 8.3.2.2.3. By End user
  • 8.3.3. Japan Human Papillomavirus (HPV) Associated Disorders Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Indication
      • 8.3.3.2.2. By Therapy
      • 8.3.3.2.3. By End user
  • 8.3.4. South Korea Human Papillomavirus (HPV) Associated Disorders Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Indication
      • 8.3.4.2.2. By Therapy
      • 8.3.4.2.3. By End user
  • 8.3.5. Australia Human Papillomavirus (HPV) Associated Disorders Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Indication
      • 8.3.5.2.2. By Therapy
      • 8.3.5.2.3. By End user

9. Middle East & Africa Human Papillomavirus (HPV) Associated Disorders Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Indication
  • 9.2.2. By Therapy
  • 9.2.3. By End user
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Human Papillomavirus (HPV) Associated Disorders Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Indication
      • 9.3.1.2.2. By Therapy
      • 9.3.1.2.3. By End user
  • 9.3.2. UAE Human Papillomavirus (HPV) Associated Disorders Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Indication
      • 9.3.2.2.2. By Therapy
      • 9.3.2.2.3. By End user
  • 9.3.3. South Africa Human Papillomavirus (HPV) Associated Disorders Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Indication
      • 9.3.3.2.2. By Therapy
      • 9.3.3.2.3. By End user

10. South America Human Papillomavirus (HPV) Associated Disorders Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Indication
  • 10.2.2. By Therapy
  • 10.2.3. By End user
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Human Papillomavirus (HPV) Associated Disorders Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Indication
      • 10.3.1.2.2. By Therapy
      • 10.3.1.2.3. By End user
  • 10.3.2. Colombia Human Papillomavirus (HPV) Associated Disorders Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Indication
      • 10.3.2.2.2. By Therapy
      • 10.3.2.2.3. By End user
  • 10.3.3. Argentina Human Papillomavirus (HPV) Associated Disorders Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Indication
      • 10.3.3.2.2. By Therapy
      • 10.3.3.2.3. By End user

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Human Papillomavirus (HPV) Associated Disorders Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Alembic Pharmaceuticals
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. AstraZeneca plc
• 15.3. Bausch Health Companies Inc
• 15.4. Biocon Ltd.
• 15.5. Bristol-Myers Squibb Co.
• 15.6. Eli Lilly and Company.
• 15.7. F. Hoffmann-La Roche Ltd
• 15.8. GlaxoSmithKline plc
• 15.9. Merck & Co., Inc.
• 15.10. Novartis AG
• 15.11. Pfizer, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer